How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

158 results for

Pancoast Tumor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Non-Small Cell Lung Cancer Treatment (PDQ®): Patient Version

-Small Cell Lung Cancer Key Points for This Section Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The are a pair of cone-shaped breathing in the chest. The lungs bring into the body as you breathe in. They release , a waste product of the body’s , as you breathe out. Each lung has sections called . The left lung has two lobes. The right lung is slightly larger and has three lobes. Two tubes called lead from the (windpipe) to the right (...) cell lung cancer spreads to the brain, the cancer cells in the brain are actually cells. The disease is metastatic lung cancer, not brain cancer. metastasis: how cancer spreads Many cancer deaths are caused when cancer moves from the original tumor and spreads to other tissues and organs. This is called metastatic cancer. This animation shows how cancer cells travel from the place in the body where they first formed to other parts of the body. The following stages are used for non-small cell lung

2018 PDQ - NCI's Comprehensive Cancer Database

42. Non-Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version

as well as epithelial and mesenchymal differentiation. On the basis of clinical and molecular data, biphasic pulmonary blastoma is regarded as part of the spectrum of carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements. Molecular features The identification of mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of subsets of patients with metastatic disease.[ ] In particular, subsets of adenocarcinoma now can be defined by specific (...) is a multistep process. Squamous cell carcinoma and adenocarcinoma have defined premalignant precursor lesions. Before becoming invasive, lung epithelium may undergo morphological changes that include the following: Hyperplasia. Metaplasia. Dysplasia. Carcinoma in situ . Dysplasia and carcinoma in situ are considered the principal premalignant lesions because they are more likely to progress to invasive cancer and less likely to spontaneously regress. In addition, after resection of a lung cancer

2018 PDQ - NCI's Comprehensive Cancer Database

43. THE RÖNTGEN DIAGNOSTIC SIGNIFICANCE OF EROSION OF THE OPTIC CANALS IN THE STUDY OF INTRACRANIAL TUMORS Full Text available with Trip Pro

THE RÖNTGEN DIAGNOSTIC SIGNIFICANCE OF EROSION OF THE OPTIC CANALS IN THE STUDY OF INTRACRANIAL TUMORS 17856445 2007 09 17 2008 11 20 0003-4932 101 1 1935 Jan Annals of surgery Ann. Surg. THE RONTGEN DIAGNOSTIC SIGNIFICANCE OF EROSION OF THE OPTIC CANALS IN THE STUDY OF INTRACRANIAL TUMORS. 246-55 Pancoast H K HK eng Journal Article United States Ann Surg 0372354 0003-4932 1935 1 1 0 0 1935 1 1 0 1 1935 1 1 0 0 ppublish 17856445 PMC1391129

1935 Annals of Surgery

44. Transcervical Technic for Removal of Specimen from Superior Sulcus Tumor for Pathologic Study Full Text available with Trip Pro

Transcervical Technic for Removal of Specimen from Superior Sulcus Tumor for Pathologic Study 14129388 1996 12 01 2018 12 01 0003-4932 159 1964 Mar Annals of surgery Ann. Surg. TRANSCERVICAL TECHNIC FOR REMOVAL OF SPECIMEN FROM SUPERIOR SULCUS TUMOR FOR PATHOLOGIC STUDY. 407-10 MCGOON D C DC eng Journal Article United States Ann Surg 0372354 0003-4932 OM Adenocarcinoma, Mucinous Adenocarcinoma, Scirrhous Biopsy Carcinoma Carcinoma, Basal Cell Carcinoma, Squamous Cell Humans Lung Neoplasms (...) Pancoast Syndrome BIOPSY CARCINOMA, BASAL CELL CARCINOMA, EPIDERMOID CARCINOMA, MUCINOUS CARCINOMA, SCIRRHOUS LUNG NEOPLASMS PANCOAST'S SYNDROME 1964 3 1 1964 3 1 0 1 1964 3 1 0 0 ppublish 14129388 PMC1408573 Cleve Clin Q. 1962 Jul;29:135-43 13902348 J Thorac Surg. 1956 May;31(5):535-42 13320532 J Am Med Assoc. 1954 Jan 23;154(4):323-6 13108717 Ann Surg. 1961 Jul;154(1):29-40 17859668

1964 Annals of Surgery

45. Clinical practice guidelines for the treatment of lung cancer

treatment option for patients with Pancoast tumours. Last reviewed December 2015 C For patients with unresectable Pancoast tumours and good performance status, the concurrent administration of chemotherapy and radiotherapy is recommended. Last reviewed December 2015 A For patients who have a poor performance status or distant metastatic disease, radiation therapy can be used to palliate symptoms due to Pancoast tumour. Last reviewed December 2015 C Stage IV operable Radiotherapy Recommendation Grade (...) ) Recommendation Grade In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended. Last reviewed December 2015 A I-125 seed brachytherapy to the tumour bed is not recommended after sublobar resection for stage I NSCLC. Last reviewed December 2015 B Practice point(s) In the absence of any evidence regarding the treatment of incompletely resected stage I disease (positive margins) unsuitable for further surgery, expert consensus opinion recommends

2016 MHRA Drug Safety Update

46. Surgery in the Treatment of Locally Advanced Lung Carcinoma Full Text available with Trip Pro

Surgery in the Treatment of Locally Advanced Lung Carcinoma 13989551 1998 11 01 2018 12 01 0040-6376 18 1963 Mar Thorax Thorax Surgery in the treatment of locally advanced lung carcinoma. 21-38 SMITH R A RA eng Journal Article England Thorax 0417353 0040-6376 OM Bronchial Fistula Esophageal Fistula Humans Lung Neoplasms Pancoast Syndrome Pneumonectomy Thoracic Cavity Vena Cava, Superior BRONCHIAL FISTULA ESOPHAGEAL FISTULA PANCOAST'S SYNDROME PNEUMONECTOMY VENA CAVA, SUPERIOR 1963 3 1 1963 3 1

1963 Thorax

47. A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

-advanced NSCLC whose disease has progressed following platinum-based sCRT. Participants who have disease considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumours. Mixed small-cell lung cancer and NSCLC histology. History of allogeneic organ transplantation. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic (...) for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by AstraZeneca: Stage III Non-Small Cell Lung Cancer Durvalumab IV infusion immunoglobulin G (IgG) Antibody-dependent cellular cytotoxicity Complement-dependent cytotoxicity Monotherapy Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung

2018 Clinical Trials

48. Locally-advanced stage III non-small-cell lung cancer (NSCLC)

at the treatmentofmicrometastasestoimprovecureratesaftercurative complete resection of the tumour at surgery. Neoadjuvant chemotherapy is de?ned as preoperative chemotherapy given to patients that are planned for a curative resection at surgery (again for improving cure rates by the early treatment of micro- metastases). The technical advances of radiotherapy allow for betterintegrationwithchemotherapyorsurgery[10]. heterogeneityintumourhistopathology There are data showing that squamous cell carcinoma patients with stage III disease tend to have a somewhat (...) central in?ltrating primary tumours without lymph node metastasis (T4N0) have a signi?cantly lower tendency to develop systemic metastatic spread than small tumours with ex- tensive mediastinal nodal involvement (e.g. T1N3) [13]. These twoentitiesarecharacteristicoftheremainingwidespectrumin morphological presentation of patients among the current stage III disease groups. These morphological differences may poten- tially represent underlying differences in individual tumour biology

2015 European Society for Medical Oncology

49. Lung Cancer

and prognosis calculator link below XVII. Resources Harvard Lung Cancer risk calculator Staging and Prognosis Calculator NCI Adult Cancer Treatment XVIII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Lung Cancer." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Bronchogenic Carcinoma (C0007121) Definition (MSH) Malignant neoplasm arising (...) from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Definition (NCI_NCI-GLOSS) Cancer that begins in the tissue that lines or covers the airways of the lungs, including small cell and non-small cell lung cancer. Definition (NCI) A lung carcinoma arising from the bronchial epithelium. Definition (NCI_CDISC) A malignant neoplasia of the lung, arising

2018 FP Notebook

50. Non-Small Cell Lung Cancer Treatment (PDQ®): Patient Version

-Small Cell Lung Cancer Key Points for This Section Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The are a pair of cone-shaped breathing in the chest. The lungs bring into the body as you breathe in. They release , a waste product of the body’s , as you breathe out. Each lung has sections called . The left lung has two lobes. The right lung is slightly larger and has three lobes. Two tubes called lead from the (windpipe) to the right (...) to the brain, the cancer cells in the brain are actually cells. The disease is metastatic lung cancer, not brain cancer. metastasis: how cancer spreads Many cancer deaths are caused when cancer moves from the original tumor and spreads to other tissues and organs. This is called metastatic cancer. This animation shows how cancer cells travel from the place in the body where they first formed to other parts of the body. The following stages are used for non-small cell lung cancer: Occult (hidden) stage

2016 PDQ - NCI's Comprehensive Cancer Database

51. Non-Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version

is a multistep process. Squamous cell carcinoma and adenocarcinoma have defined premalignant precursor lesions. Before becoming invasive, lung epithelium may undergo morphological changes that include the following: Hyperplasia. Metaplasia. Dysplasia. Carcinoma in situ . Dysplasia and carcinoma in situ are considered the principal premalignant lesions because they are more likely to progress to invasive cancer and less likely to spontaneously regress. In addition, after resection of a lung cancer (...) for diagnosis and subclassification, but most lung tumors can be classified by light microscopic criteria. (Refer to the section of this summary for more information on tests and procedures used for staging.) Molecular Features The identification of mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of subsets of patients with metastatic disease.[ ] In particular, subsets of adenocarcinoma now can be defined by specific mutations in genes encoding

2016 PDQ - NCI's Comprehensive Cancer Database

52. En bloc resection of 3 vertebra in a pancoast patient: long-term stability using a free vascularized fibular graft. (Abstract)

En bloc resection of 3 vertebra in a pancoast patient: long-term stability using a free vascularized fibular graft. Vertebral involvement is no longer a contraindication for resection in superior sulcus tumors. We describe the reconstruction of thoracic vertebras 2 to 4 using a free vascularized fibular graft combined with dorsal and ventral stabilization using rods, screws, and hooks after resection of a superior sulcus tumor that invaded the thoracic spine. No complications have occurred

2011 Annals of Thoracic Surgery

53. Lung Carcinoma

pathways that supply oxygen and nutrition to growing tumor cells. Table Some Targeted Therapy Drugs for Non–Small Cell Lung Cancer Target Drug NSCLC ALK rearrangement Alectinib Brigatinib Ceritinib Crizotinib Adenocarcinoma BRAF mutation Dabrafenib Trametinib Adenocarcinoma Squamous cell carcinoma EGFR mutation Afatinib Erlotinib Gefitinib Necitumumab Adenocarcinoma Squamous cell carcinoma EGFR (T790M mutation) Osimertinib Adenocarcinoma Inhibit blood vessel growth Bevacizumab Ramucirumab (...) Adenocarcinoma Immune activation (checkpoint inhibitors) Atezolizumab Nivolumab Pembrolizumab Adenocarcinoma Squamous cell carcinoma NSCLC = Non–small cell lung cancer. Recurrent lung cancer Treatment options for lung cancer that recurs after treatment vary by location and include repeat chemotherapy or targeted drugs for metastases, radiation therapy for local recurrence or pain caused by metastases, and brachytherapy for endobronchial disease when additional external radiation cannot be tolerated. Rarely

2013 Merck Manual (19th Edition)

54. INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer

methods are a condom or a diaphragm with spermicidal jelly, or oral, injectable or implanted birth control. Provision of written consent in line with ICH-GCP guidelines Exclusion Criteria: Previous thoracic radiation therapy Known co-existing or prior malignancy which is likely to interfere with treatment or assessment of outcomes Known distant metastases or metastatic pleural effusion Pancoast tumours (tumour of the pulmonary apex) Supraclavicular nodal involvement Spinal cord involvement Patients (...) : No Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms

2016 Clinical Trials

55. Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer

suspected non-small cell lung cancer (NSCLC) Potentially operable Exclusion Criteria: M1 disease Inoperable T4 disease Mediastinal infiltration or extranodal invasion of the mediastinal lymph node visible on chest CT Confirmed supraclavicular lymph node metastasis Pancoast tumours T1 ground glass opacity nodule (with solid part 1cancer staging Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms

2016 Clinical Trials

56. Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer

to the quality of life and the costs they generate. Patients who agree to participate in the study were assigned to one or other of these groups (technical thoracotomy or video-thoracoscopy technique) by lot. Condition or disease Intervention/treatment Phase Lung Cancer Lobectomy Procedure: Video-thoracoscopy Procedure: thoracotomy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 600 participants Allocation: Randomized (...) Inclusion Criteria: Patients who have given their consent Any patient with proven or suspected lung cancer treated by lobectomy. Patients with a negative mediastinoscopy or negative " EBUS-EUS " following a PET scan showing uptake in mediastinal lymph nodes in the preoperative examination. Age between 18 and 80 years Patient affiliated to a social security regimen Patients with a WHO performance status equal to 0 or 1. Exclusion Criteria: Adults under wardship Pregnant or breast-feeding women Tumours

2015 Clinical Trials

57. Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

of the study including undergoing treatment and scheduled visits and examinations including follow-up. Exclusion Criteria: Presence of any distant metastasis or N3 disease. Brain metastases have to be excluded by CT or MRI. Sulcus superior tumors (Pancoast tumors). Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical carcinoma in situ. Any previous treatment for NSCLC. Any previous treatment with a PD-1 (...) ) Sharing Statement: Plan to Share IPD: No Keywords provided by Swiss Group for Clinical Cancer Research: NSCLC lung cancer MEDI4736 non-small cell lung cancer immunotherapy anti-PD-L1 Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Durvalumab Antibodies, Monoclonal Antineoplastic Agents

2015 Clinical Trials

58. Special Treatment Issues in Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Full Text available with Trip Pro

Special Treatment Issues in Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. This guideline updates the second edition and addresses patients with particular forms of non-small cell lung cancer that require special considerations, including Pancoast tumors, T4 N0,1 M0 tumors, additional nodules in the same lobe (T3), ipsilateral different lobe (T4) or contralateral lung (M1a (...) possible, we also reference other consensus opinion statements. Recommendations were developed by the writing committee, graded by a standardized method, and reviewed by all members of the Lung Cancer Guidelines panel prior to approval by the Thoracic Oncology NetWork, Guidelines Oversight Committee, and the Board of Regents of the American College of Chest Physicians.In patients with a Pancoast tumor, a multimodality approach appears to be optimal, involving chemoradiotherapy and surgical resection

2013 Chest

59. Non-Small Cell Lung Cancer

reflects a continuum in histologic heterogeneity as well as epithelial and mesenchymal differentiation. On the basis of clinical and molecular data, biphasic pulmonary blastoma is regarded as part of the spectrum of carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements. Molecular features The identification of mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of subsets of patients with metastatic disease.[ ] In particular, subsets (...) with permission from AJCC: Lung. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual . 8th ed. New York, NY: Springer, 2017, pp 431–56. Occult carcinoma TX, N0, M0 TX = Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy. N0 = No regional lymph node metastasis. M0 = No distant metastasis. T = primary tumor; N = regional lymph node; M = distant metastasis. Table 2. Definitions

2012 PDQ - NCI's Comprehensive Cancer Database

60. Treatment of pancoast tumors from the surgeons prospective: re-appraisal of the anterior-manubrial sternal approach Full Text available with Trip Pro

Treatment of pancoast tumors from the surgeons prospective: re-appraisal of the anterior-manubrial sternal approach Pancoast tumours are now amenable to multimodality treatment with an acceptable survival. This is because trimodality treatment improves tumor sterilization and hence outcome. Moreover the development of an anterior approach to access the tumor, further improved the technical challenges for a sound resection.The Anterior-manubrial sternal approach was described more than a decade

2010 Journal of cardiothoracic surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>